Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B

Pharmacotherapy

Volumn 18, Issue 4, 1998, Pages 874-876

  Barcia, John P ^a  

^a Legacy Emanuel Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CEFOTAXIME; DIPHENHYDRAMINE; FLUCYTOSINE; PARACETAMOL; POTASSIUM CHLORIDE;

ARTICLE; CANDIDIASIS; CARDIOPULMONARY ARREST; CASE REPORT; DRUG FORMULATION; FEMALE; HUMAN; HYPERKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CANDIDIASIS; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERKALEMIA; INFUSIONS, INTRAVENOUS; MALE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS;

EID: 0031852583     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Liposome Co. Abelcet (amphotericin B lipid complex) package insert. Princeton, NJ;1997.
2. Ellis ME, Al-Hokail AA, Clink HM, et al. Double-blind randomized study of the effect of infusion rates on the toxicity of amphotericin B. Antimicrob Agents Chemother 1992;36: 172-9.
3. Oldfield EC, Garst PD, Hostettler C, White M, Samuelson D. Randomized, double-blind trial of 1- versus 4- hour amphotericin B infusion duration. Antimicrob Agents Chemother 1990;34:1402-6.
4. Cleary JD, Weisdorf D, Fletcher CV. Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell Clin Pharm 1988;22:769-72.
5. Spitzer TR, Creger RJ, Fox RM, Lazarus HM. Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic fever. Pharmatherapeutica 1989;5:305-11.
6. Davies HD, King SM, Doyle J, et al. Controlled pilot study of rapid amphotericin B infusions. Arch Dis Child 1997;76: 165-6.
7. Bowler WA, Weiss PJ, Hill HE, et al. Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal function. Antimicrob Agents Chemother 1992;36:2542-3.
8. Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother 1985;27:868-71.
9. Butler WT, Bennett JE, Hill GJ, Szwed CF, Cotlove E. Electrocardiographic and electrolyte abnormalities caused by amphotericin B in dog and man. Proc Soc Exp Biol Med 1964;116:857-63.
10. Feldman HA, Hamilton JD, Gutman RA. Amphotericin B therapy in an anephric patient. Antimicrob Agents Chemother 1973;4:302-5.
11. DeMonaco HJ, McGovern B. Transient asystole associated with amphotericin B infusion. Drug Intell Clin Pharm 1983;17: 547-8.
12. Aguado JM, Hidalgo M, Moya I, Alcazar JM, Jimenez MJ, Noriega AR. Ventricular arrhythmias with conventional and liposomal amphotericin. Lancet 1993;342:1239.
13. Cleary JD, Hayman J, Sherwood J, Lasala GP, Piazza-Hepp T. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother 1993;27:715-18.
14. Soler JA, Iban L, Zuazu J, Julia A. Bradycardia after rapid infusion of amphotericin B. Lancet 1993;341:372-3.
15. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Bernstein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991;114:664-6.
16. Fields BT, Bates JH, Abernathy RS. Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Appl Microbiol 1971;22:615-17.
17. Carlson MA, Condon RE. Nephrotoxicity of amphotericin B. J Am Coll Surg 1994;179:361-81.
18. de Marie S, Janknegt R, Bakker-Woudenherg IA. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994;33:907-16.
19. Anonymous. Abelcet®. Physicians' desk reference. Oradell, NJ: Medical Economics, 1998:1516-17.
20. Gale EF. The release of potassium ions from Candida albicans in the presence of polyene antibiotics. J Gen Microbiol 1974;80:451-65.